Abstract

HERBAMIG in the prevention of migraine headaches: results of a study based on real-life data.

Author(s): Rémi Shrivastava, Séverine Dameron

Background: Migraine is a widespread neurological disorder, affecting approximately 12% of the global population, with significant socioeconomic and personal impacts. The underdiagnosis and undertreatment of migraines exacerbate the burden, highlighting the need for effective preventive treatments. Dietary supplements, such as Tanacetum parthenium (feverfew), Salix alba (willow bark), vitamins B2 and B12, and coenzyme Q10, have shown potential benefits in migraine prevention.

Objective: This study aimed to evaluate the efficacy and safety of HERBAMIG, a dietary supplement combining these ingredients, in preventing migraine headaches.

Methods: A 3 month observational clinical follow-up was conducted in France, involving 302 participants diagnosed with episodic migraine. Patients took one capsule of HERBAMIG daily, containing 90 mg of feverfew, 150 mg of willow bark, 40 mg of coenzyme Q10, 15 mg of riboflavin, and 0.1 mg of cyanocobalamin. Primary endpoint was the change in the number of migraine days per month. Secondary endpoints included changes in migraine intensity, duration, Headache Impact Test (HIT6), and Migraine Disability Assessment Scale (MIDAS) scores.

Results: Out of 302 enrolled patients, 256 completed the study. HERBAMIG significantly reduced the number of migraine days by 28.4% (from 8.1 ± 2.5 to 5.8 ± 2.4 days per month, p<0.001). Migraine intensity decreased by 2.1 points on a 10-point scale (from 7.8 ± 1.4 to 5.7 ± 1.8, p<0.001), and duration reduced by 2.2 hours (from 17.3 ± 7.0 to 15.1 ± 6.9 hours, p<0.001). Significant improvements were observed in HIT-6 (decrease of 4.8 ± 0.6 points, p<0.001) and MIDAS scores (decrease of 5.2 ± 0.4 points, p<0.001). Adverse events were mild and transient, with no serious side effects reported.

Conclusion: HERBAMIG, a combination of feverfew, willow bark, riboflavin, cyanocobalamin, and coenzyme Q10, effectively reduces the frequency, intensity, and duration of migraines, significantly improving patients' quality of life. Further research is warranted to confirm these findings and elucidate the mechanisms of action.